Principal Financial Group Inc. Buys 3,248 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Principal Financial Group Inc. lifted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 3.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,865 shares of the medical instruments supplier's stock after purchasing an additional 3,248 shares during the period. Principal Financial Group Inc. owned about 0.50% of LeMaitre Vascular worth $9,385,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in LMAT. Opal Wealth Advisors LLC acquired a new position in shares of LeMaitre Vascular during the first quarter worth $26,000. NBC Securities Inc. acquired a new stake in LeMaitre Vascular in the first quarter valued at $36,000. Huntington National Bank increased its stake in LeMaitre Vascular by 64.9% during the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after purchasing an additional 455 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in LeMaitre Vascular by 112.5% during the fourth quarter. Canada Pension Plan Investment Board now owns 1,700 shares of the medical instruments supplier's stock valued at $157,000 after purchasing an additional 900 shares during the last quarter. Finally, Summit Investment Advisors Inc. increased its stake in LeMaitre Vascular by 8.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 2,122 shares of the medical instruments supplier's stock valued at $196,000 after purchasing an additional 160 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Performance

LMAT stock traded down $1.88 during trading on Friday, hitting $80.22. 41,900 shares of the company's stock traded hands, compared to its average volume of 168,563. The company has a quick ratio of 13.83, a current ratio of 16.49 and a debt-to-equity ratio of 0.48. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The stock has a fifty day moving average price of $82.83 and a two-hundred day moving average price of $87.86. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of 40.50, a price-to-earnings-growth ratio of 2.18 and a beta of 0.82.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). The firm had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The firm's revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.44 EPS. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's payout ratio is 40.40%.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 4,399 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total transaction of $374,354.90. Following the completion of the sale, the chief executive officer directly owned 1,827,003 shares of the company's stock, valued at approximately $155,477,955.30. This represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders have sold 100,000 shares of company stock valued at $8,556,857. 9.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.